Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?

Literature DB >> 25944636

Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?

Uwe Platzbecker¹, Pierre Fenaux².

Abstract

Entities: Disease

Mesh：

Year: 2015 PMID： 25944636 PMCID： PMC4420204 DOI： 10.3324/haematol.2015.126813

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

20 in total

1. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

Authors: Martin Jädersten; Leonie Saft; Alexander Smith; Austin Kulasekararaj; Sabine Pomplun; Gudrun Göhring; Anette Hedlund; Robert Hast; Brigitte Schlegelberger; Anna Porwit; Eva Hellström-Lindberg; Ghulam J Mufti
Journal: J Clin Oncol Date: 2011-04-25 Impact factor: 44.544

2. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors: Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245

3. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes.

Authors: Emilie Frisan; Patrycja Pawlikowska; Cecile Pierre-Eugène; Vivian Viallon; Laure Gibault; Sophie Park; Patrick Mayeux; François Dreyfus; Françoise Porteu; Michaëla Fontenay
Journal: Haematologica Date: 2010-09-07 Impact factor: 9.941

4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors: Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal: Blood Date: 2010-10-12 Impact factor: 22.113

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316

6. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.

Authors: Eva Hellström-Lindberg; Nina Gulbrandsen; Greger Lindberg; Tomas Ahlgren; Inger Marie S Dahl; Ingunn Dybedal; Gunnar Grimfors; Eva Hesse-Sundin; Martin Hjorth; Lena Kanter-Lewensohn; Olle Linder; Michaela Luthman; Eva Löfvenberg; Gunnar Oberg; Anja Porwit-MacDonald; Anders Rådlund; Jan Samuelsson; Jon Magnus Tangen; Ingemar Winquist; Finn Wisloff
Journal: Br J Haematol Date: 2003-03 Impact factor: 6.998

7. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.

Authors: Lionel Adès; Simone Boehrer; Thomas Prebet; Odile Beyne-Rauzy; Laurence Legros; Christophe Ravoet; François Dreyfus; Aspasia Stamatoullas; Marie Pierre Chaury; Jacques Delaunay; Guy Laurent; Norbert Vey; Sara Burcheri; Rose-Marie Mbida; Natacha Hoarau; Claude Gardin; Pierre Fenaux
Journal: Blood Date: 2008-11-05 Impact factor: 22.113

8. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.

Authors: Arjan A van de Loosdrecht; Canan Alhan; Marie Christine Béné; Matteo G Della Porta; Angelika M Dräger; Jean Feuillard; Patricia Font; Ulrich Germing; Detlef Haase; Christa H Homburg; Robin Ireland; Joop H Jansen; Wolfgang Kern; Luca Malcovati; Jeroen G Te Marvelde; Ghulam J Mufti; Kiyoyuki Ogata; Alberto Orfao; Gert J Ossenkoppele; Anna Porwit; Frank W Preijers; Stephen J Richards; Gerrit Jan Schuurhuis; Dolores Subirá; Peter Valent; Vincent H J van der Velden; Paresh Vyas; August H Westra; Theo M de Witte; Denise A Wells; Michael R Loken; Theresia M Westers
Journal: Haematologica Date: 2009-06-22 Impact factor: 9.941

9. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment.

Authors: Theresia M Westers; Canan Alhan; Martine E D Chamuleau; Maurice J D L van der Vorst; Corien Eeltink; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal: Blood Date: 2009-12-28 Impact factor: 22.113